Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TheraVida and SK Chemicals have entered into a licensing deal for the development and commercialization of THVD-201 and THVD-202 in South Korea.
Subscribe to our email newsletter
According to the deal, SK Chemicals is responsible for clinical development, approval, and commercialization of THVD-201 and THVD-202 drug candidates to treat overactive bladder (OAB) and urge urinary incontinence (UUI).
SK Chemicals Life Science Business Group chief executive officer In-Serk Lee said, "We believe THVD-201 has demonstrated a highly differentiated clinical profile, relative to tolterodine, which has been confirmed by an international Phase 2 clinical trial."
SK will bear all the costs associated with manufacturing, development, approval, and commercialization of the products in South Korea. TheraVida is eligible for milestone payments besides royalty on net sales of the products.
THVD-201 is a proprietary twice-daily (BID) formulation of tolterodine and pilocarpine while THVD-202 is a proprietary once-daily (QD) formulation of tolterodine and pilocarpine.
THVD-201 has completed Phase 1 and Phase 2 development in international clinical trials and THVD-202 is completing pre-clinical development.
TheraVida chief executive officer Roger Flugel said, "THVD-201 and THVD-202 have the potential to offer significant improvement in dry mouth side effects and better efficacy over current standard-of-care therapies for OAB and UUI."